China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Xgeva Gains Europe’s Approval for Preventing Bone Lesions in Multiple Myeloma
The European Commission has extended Xgeva‘s (denosumab) approval for the prevention of bone lesions in multiple myeloma patients, Amgen, the medicine’s maker, announced. The…
Xgeva Use in Myeloma May Be Expanded to Europe Following Positive CHMP Opinion
Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from…
FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
FDA Will Review Amgen’s Request to Expand Use of Xgeva for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
